KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Expenses (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Accumulated Expenses for 4 consecutive years, with $3.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Accumulated Expenses changed N/A year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Sep 2023, changed N/A, and an annual FY2022 reading of $19.3 million, down 14.04% over the prior year.
  • Accumulated Expenses was $3.1 million for Q3 2023 at AbCellera Biologics, roughly flat from $3.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $45.4 million in Q1 2022 and bottomed at $595000.0 in Q3 2021.
  • Average Accumulated Expenses over 4 years is $16.8 million, with a median of $19.7 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 126.71% in 2022, then crashed 93.18% in 2023.
  • Year by year, Accumulated Expenses stood at $27.1 million in 2020, then decreased by 17.08% to $22.5 million in 2021, then decreased by 14.04% to $19.3 million in 2022, then plummeted by 84.01% to $3.1 million in 2023.
  • Business Quant data shows Accumulated Expenses for ABCL at $3.1 million in Q3 2023, $3.1 million in Q2 2023, and $3.1 million in Q1 2023.